BPK2139 Citations (3)

Originally described in: Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, Gonzales AP, Li Z, Peterson RT, Yeh JJ, Aryee MJ, Joung JK Nature. 2015 Jun 22. doi: 10.1038/nature14592. PubMed Journal

---

Articles Citing BPK2139

Articles
Increasing the specificity of CRISPR systems with engineered RNA secondary structures. Kocak DD, Josephs EA, Bhandarkar V, Adkar SS, Kwon JB, Gersbach CA. Nat Biotechnol. 2019 Jun;37(6):657-666. doi: 10.1038/s41587-019-0095-1. Epub 2019 Apr 15. PubMed
Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease. Khosravi MA, Abbasalipour M, Concordet JP, Berg JV, Zeinali S, Arashkia A, Azadmanesh K, Buch T, Karimipoor M. Eur J Pharmacol. 2019 Jul 5;854:398-405. doi: 10.1016/j.ejphar.2019.04.042. Epub 2019 Apr 27. PubMed
Expression analysis data of BCL11A and gamma-globin genes in KU812 and KG-1 cell lines after CRISPR/Cas9-mediated BCL11A enhancer deletion. Khosravi MA, Abbasalipour M, Concordet JP, Berg JV, Zeinali S, Arashkia A, Buch T, Karimipoor M. Data Brief. 2019 Dec 11;28:104974. doi: 10.1016/j.dib.2019.104974. eCollection 2020 Feb. PubMed

If you have published an article using this material, please email us at to have your article added to this page.